T cell costimulation blockade blunts pressure overload-induced heart failure. Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Endomyocardial Biopsy Characterization of Heart Failure with Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Cardiac macrophages promote diastolic dysfunction.

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients with HFpEF. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial.

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Evaluation and management of heart failure with preserved ejection fraction. Temporal Trends in the Incidence of and Mortality Associated with Heart Failure with Preserved and Reduced Ejection Fraction. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017.The authors declare no conflict of interest.

16 segment display font